eTheRNA CEO outlines development plan in cancer RNA space

November 24, 2016 Christoph Graener

Mike Ward, global director of content for Informa Pharma Intelligence, interviews Dirk Reyn, CEO of eTheRNA, on the sidelines of the BIO-Europe® partnering conference in Cologne, Germany. The pair discusses eTheRNA’s emerging cancer immunotherapy pipeline, funding prospects and the next steps for the company—which was founded in 2013—as it looks to expand its business.

  

  

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Dirk Reyn – President and CEO, eTheRNA

 

Previous Article
Freshly-appointed Auspherix CEO highlights new antibiotic class
Freshly-appointed Auspherix CEO highlights new antibiotic class

Auspherix’s newly-appointed CEO talks about the science behind the company’s gram-negative targeting new an...

Next Article
BioNTech’s Sean Marett explains Genentech deal rationale
BioNTech’s Sean Marett explains Genentech deal rationale

Chief operating officer of BioNTech, Sean Marett, talks about the German firm's recent co-development deal ...